Tamtam Try Tamtam free
Neogen Corporation logo

Neogen Corporation account plan

Food safety solutions and services

At a glance

Neogen makes food safety diagnostics and animal safety products; FY2026 revenue was $870.4 million with 2,636 employees.

Neogen Corporation (NASDAQ: NEOG, Lansing, Michigan) develops and sells food safety diagnostics, including Petrifilm, culture media, pathogen, allergen and toxin tests and Clean-Trace hygiene monitoring, plus animal safety products such as veterinary instruments, animal care and rodent and insect control. Its customers are food and feed producers, processors, laboratories, regulators, veterinarians and livestock producers, served directly in 28 countries outside the U.S. and through distributors in more than 100 countries. FY2026 (year to May 31, 2026) revenue was $870.4 million and the net loss $7.9 million; sales outside the U.S. were 51.2% of revenue. It had 2,636 employees at May 31, 2026.

Business units

Strategic priorities

Bringing Petrifilm manufacturing in-house
Petrifilm production moves from 3M plants to Neogen's Lansing site; the first SKU was fully validated in August 2026 and the multi-quarter transition of 17 SKUs starts in November 2026. The CFO talked about 200 to 300 basis points of gross margin expansion once fully ramped.
Commercial excellence
A new model under CCO Joe Friels focuses on 14 priority countries, a dedicated strategic account function, solutions-based selling and e-commerce for the long tail; about 40% of Food Safety revenue already flows through e-commerce.
Rebuilding innovation
R&D spending rises about 50% in FY2027, with a long-term aim of approaching 5% of revenue, led by CSO Jeremy Yarwood; a Petrifilm innovation line at Oakdale, Minnesota should allow two new Petrifilm SKUs a year.
Margin expansion and efficiency
The long-term objective is approximately 30% adjusted EBITDA margins, with $25 million of transformation spending in FY2027 and AI and automation planned in customer service, finance, planning, R&D and technical service.
Debt reduction
About $140 million of net Genomics proceeds go to debt reduction and investment, with net leverage targeted close to 2.5 times by the end of FY2027.

Latest results

In Q1 FY2027 (three months to August 31, 2026), revenue was $222.8 million, up 6.5% from $209.2 million, with core growth of 8.1%, about 3% of which came from prior-year distributor inventory adjustments and order timing. Food Safety grew 7.4% and Animal Safety 4.2%, and every region grew. Gross margin rose to 47.4% from 45.4% and adjusted EBITDA was $41.6 million (18.7% margin); the GAAP net loss was $11.9 million. FY2027 guidance was raised to revenue of $885-$890 million and adjusted EBITDA of $181-$183 million.

Investments and deals

Lansing Petrifilm plant
The new Lansing facility nears completion; capex was $51.3 million in FY2026 and is estimated at about $40 million in FY2027.
Cleaners and Disinfectants divestiture
Sold to Kersia Group in Q1 FY2026 for $121.7 million in cash plus an earnout of up to $3.5 million; proceeds went to debt repayment.
Genomics divestiture
Agreed on March 2, 2026 to sell Genomics to Zoetis for $160.0 million; the ACCC and NZCC reviews are expected to conclude by the end of December 2026.
Hinalea Imaging collaboration
An equity investment and collaboration to develop hyperspectral digital imaging for food safety and quality inspection, announced with Q1 FY2027 results.
Sample collection automation
A new sample collection automation line is planned for fiscal 2028, after sample collection ran at a negative gross margin.

Challenges and risks

Petrifilm transition risk
The move from 3M plants may be delayed or run over cost, and duplicative costs continue until it completes ($9.8 million more in Food Safety in FY2026); the 3M agreement runs to August 2027 as a backstop.
Supplier dependence
Animal Safety core revenue fell 8.7% in Q3 FY2026 because of third-party supplier disruptions, including an instrument supplier moving sites, the global vitamin A shortage and a sodium bicarb partner.
Tariffs and input costs
Tariffs raise costs on imported materials and hurt international sales of U.S.-made products; freight costs rose about $1.5 million per quarter.
Debt and covenants
Debt was about $800.0 million at May 31, 2026 against cash of $185.5 million, with covenants on funded debt to EBITDA and debt service coverage.
Weak end markets and leadership change
The Animal Safety end market remains near cyclical lows, food producers face inflation, and the 10-K cites significant recent management transitions.

What leadership says

“Build Neogen into the undisputed global food safety category leader.”

Mikhael Nassif, President & Chief Executive Officer · Q4 and full-year fiscal 2026 earnings call, July 30, 2026

“strengthening commercial discipline, harmonizing our sales operating model, rebuilding our innovation engine”

Mikhael Nassif, President & Chief Executive Officer · Q1 FY2027 results press release, October 6, 2026

“our challenges are operational. They're internally related.”

Mikhael Nassif, President & Chief Executive Officer · Q3 fiscal 2026 earnings call, April 9, 2026

“We're going more top to top now”

Mikhael Nassif, President & Chief Executive Officer · Q4 and full-year fiscal 2026 earnings call, July 30, 2026

Where a supplier can help

Manufacturing ramp support
Tied to the Petrifilm in-house transition: equipment, validation, quality and automation suppliers can help ramp 17 SKUs in Lansing and the planned sample collection automation line.
Sales operations and e-commerce tools
Tied to the commercial excellence priority: CRM, KPI tracking, strategic account and e-commerce platforms fit a model built on priority countries, top-to-top selling and serving the long tail online.
AI and automation in back-office functions
Tied to the margin expansion priority: with about 56% of operating expenses in salaries and benefits, AI for customer service, finance and planning addresses a stated cost lever.
Supplier qualification and sourcing
Tied to the supplier dependence challenge: alternative or dual sources for instruments and raw materials reduce the disruptions that hit Animal Safety.
R&D and technology licensing
Tied to the innovation priority: R&D partners and licensors from adjacent markets such as human healthcare can feed next-generation pathogen detection and sanitation platforms.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Neogen Corporation?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Neogen Corporation

What does Neogen do?

Neogen makes food safety diagnostics such as Petrifilm, culture media, pathogen and allergen tests, and animal safety products such as veterinary instruments and rodent and insect control.

What is Neogen's revenue?

FY2026 revenue (year to May 31, 2026) was $870.4 million. FY2027 revenue is guided at $885-$890 million.

How many employees does Neogen have?

Neogen had 2,636 employees at May 31, 2026, after a restructuring that cut about 10% of global headcount.

Who leads Neogen?

Mikhael Nassif is President and CEO, R. Bryan Riggsbee is CFO and James C. Borel is Chairman of the Board.

What is Neogen's strategy?

Neogen's FY2027 plan rests on commercial excellence, innovation and operational efficiency, with Petrifilm manufacturing moving in-house and the Genomics business being sold to Zoetis.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)